Expanding studies to investigate ERM proteins, AMH/inhibin dynamics, proliferation indices, and FOXL2 status across tumor subtypes holds promise for enhancing prognostic stratification and informing tailored postoperative management in equine practice. This evidence concerns the gene AMH and neoplasm.